• our science is driven by understanding and utilizing endogenous signalling pathways
  • our drug candidates are highly potent and stable analogues

Novel therapeutic strategy

OMEICOS Therapeutics is developing novel, first-in-class, orally available small molecules utilizing a new Mode of Action.
 
It is our goal to utilize our proprietary technology and knowledge of the body’s own omega-3 fatty acid metabolic processes for the development of therapeutics that benefit patients suffering from medically underserved diseases.

Latest news

Meet us at Bio-Europe 2016

Conference Website
November 7-9, 2016 

Cologne, Germany

 

OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation

Berlin, Germany, November 2, 2015

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation, today announced the approval of an approximately €1.7 million grant by the German Ministry of Education and Research (BMBF). The grant covers half of the investment needed to advance an OMEICOS’ research project with the other half coming from the funds secured in a Series A round from an investor consortium including Vesalius Biocaptial II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gruenderfonds II GmbH & Co. KG (HTGF) and KfW Group earlier this year. The project will facilitate further research activities into OMEICOS’ novel approach to treat atrial fibrillation using orally available small molecule drug candidates and to explore their potential in other areas of high unmet medical need.

read more ...

OMEICOS Appoints Dr. Ulrich Dauer as Chief Executive Officer

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced the appointment of Dr. Ulrich Dauer as Chief Executive Officer, effective April 13, 2015.

read more ...

OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation

Berlin, Germany, April 15, 2015

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced that it has raised EUR 6.2 million in a Series A round. Participating in the round were Vesalius Biocapital II S.A. SICAR, acting as lead; a SMS Group Company; VC Fonds Technologie Berlin; Hightech Gruenderfonds II GmbH & Co. KG (HTGF); and KfW Group. As part of the financing round, the company has received subsidies of EUR 550,000 via Ascenion's Spinnovator, a grant program supported by the German Ministry of Education and Research (BMBF).

"The growing population of AF patients is faced with outdated and extremely limited medical treatment options. Current treatments have insufficient efficacy, risk of severe side effects, and are unable to reduce patient mortality," said Dr. Robert Fischer, Chief Scientific Officer of OMEICOS Therapeutics. "We are grateful for the recognition from our investors that OMEICOS has the potential to develop truly novel drugs to prevent and treat severe cardiovascular diseases such as AF."

read more ...